<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123612</url>
  </required_header>
  <id_info>
    <org_study_id>61806</org_study_id>
    <nct_id>NCT05123612</nct_id>
  </id_info>
  <brief_title>Maternal &amp; Offspring Microbiome Study</brief_title>
  <acronym>MOMS</acronym>
  <official_title>Effects of Fermented &amp; Fiber-rich Foods on Maternal &amp; Offspring Microbiome Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn how different dietary interventions affect microbiota&#xD;
      diversity in pregnant women and the transmission of microbiota to their infants during&#xD;
      pregnancy, birth, and postpartum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study aims to understand the relationship of dietary fiber, fermented foods,&#xD;
      and the microbiome, specifically during pregnancy and postpartum. We know that the&#xD;
      composition of the microbiome can have an important effect on our overall health, and a&#xD;
      greater variety will confer more health benefits. Research suggests that maternal microbiota&#xD;
      play an important role in the development of their offspring's microbiota during pregnancy,&#xD;
      childbirth, and breastfeeding. The purpose of this study is to assess how diet impacts&#xD;
      maternal microbiome during pregnancy and their infant's microbiome up to about two years&#xD;
      postpartum.&#xD;
&#xD;
      Potential pregnant participants will be recruited during their first trimester up to 22&#xD;
      weeks. After completion of the baseline visit and sample collection, they will be randomized&#xD;
      to start a diet high in fiber, high in fermented foods, high in both fiber and fermented&#xD;
      foods, or a usual care group. Participants will be asked to provide blood, stool, vaginal&#xD;
      swab, and breast milk samples periodically throughout the study. Cord blood will be collected&#xD;
      after childbirth, and infant blood from a heel stick will be collected twice. They will also&#xD;
      be asked to fill out online questionnaires and perform dietary recalls with study diet&#xD;
      assessors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in total number of species detected in stool as a measure of infant microbiota diversity.</measure>
    <time_frame>1 month postpartum</time_frame>
    <description>Difference in total number of species (ASVs - Amplicon Sequence Variants) detected in stool between the fiber, fermented, fiber + fermented and comparator arms at 1 month postpartum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the total number of species detected in stool as a measure of maternal microbiota diversity.</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change in differences in total number of species (ASVs- Amplicon Sequence Variants) detected in stool from baseline to 36 weeks of pregnancy between fiber, fermented, fiber + fermented, and comparator arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the maternal inflammatory marker profile</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change in the differences in inflammatory markers (β-NGF, LIF-R, IL-12B, IL10, CASP-8, LAP TGF-β-1, CD6, CD5, MCP-2, IL6, CCL20, IL18, VEGFA, MMP-10, MCP-4, CCL4, CXCL10, CCL19, FGF-21) detected in blood samples from baseline to 36 weeks of pregnancy between fiber, fermented, fiber + fermented, and comparator arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the infant inflammatory marker profile</measure>
    <time_frame>6 months postpartum</time_frame>
    <description>Difference in amount of inflammatory markers (β-NGF, LIF-R, IL-12B, IL10, CASP-8, LAP TGF-β-1, CD6, CD5, MCP-2, IL6, CCL20, IL18, VEGFA, MMP-10, MCP-4, CCL4, CXCL10, CCL19, FGF-21) detected in heel stick blood between fiber, fermented, fiber + fermented, and comparator arms at 6 months postpartum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the infant allergy marker profile</measure>
    <time_frame>6 months postpartum</time_frame>
    <description>Difference in amount of allergy markers (skin prick testing) detected in heel stick blood between fiber, fermented, fiber + fermented, and comparator arms at 6 months postpartum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant Growth</measure>
    <time_frame>18 months postpartum</time_frame>
    <description>Difference in weight-for-length growth chart percentiles between fiber, fermented, fiber + fermented, and comparator arms at 18 months postpartum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Weight</measure>
    <time_frame>36 weeks of pregnancy</time_frame>
    <description>Differences in the number of participants who gained weight within the pregnancy weight gain recommendations between fiber, fermented, fiber + fermented, and comparator arms measured at 36 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal systolic blood pressure</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change from baseline in systolic blood pressure at 36 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal diastolic blood pressure</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change from baseline in diastolic blood pressure at 36 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal LDL-cholesterol</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change from baseline in LDL cholesterol at 36 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal HDL-cholesterol</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change from baseline in HDL cholesterol at 36 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal triglycerides</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change from baseline in triglycerides at 36 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal glucose</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change from baseline in glucose at 36 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal fasting insulin</measure>
    <time_frame>Baseline and 36 weeks of pregnancy</time_frame>
    <description>Change from baseline in fasting insulin at 36 weeks of pregnancy.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Microbiome</condition>
  <condition>Immune Function</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Fiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to increase their usual dietary fiber intake by 20 grams/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fermented Foods</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to consume 6 servings of fermented foods per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fiber + Fermented Foods</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to increase their usual dietary fiber intake by 20 grams/day and to consume 6 servings of fermented foods per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive usual care for pregnancy and postpartum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fiber</intervention_name>
    <description>Additional 20 grams of fiber/day.</description>
    <arm_group_label>Fiber</arm_group_label>
    <arm_group_label>Fiber + Fermented Foods</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fermented Foods</intervention_name>
    <description>6 servings of fermented foods/day</description>
    <arm_group_label>Fermented Foods</arm_group_label>
    <arm_group_label>Fiber + Fermented Foods</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Singleton pregnancies&#xD;
&#xD;
          -  Recruit during the first trimester and up to 22 weeks of pregnancy.&#xD;
&#xD;
          -  Healthy subjects willing and able to provide blood, stool, vaginal swab, and breast&#xD;
             milk samples.&#xD;
&#xD;
          -  Must be able to provide signed and dated informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-pregnancy BMI greater than 40&#xD;
&#xD;
          -  Blood pressure SBP: &gt; 160 mmHg -OR- DBP: &gt; 90 mmHg&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Symptomatic gallstones&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Acute disease at time of enrollment (i.e. flu or gastroenteritis). May delay sampling&#xD;
             until subject recovers.&#xD;
&#xD;
          -  Chronic, clinically significant, unstable (unresolved, requiring on-going changes to&#xD;
             medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic&#xD;
             or renal functional abnormality, as determined by medical history&#xD;
&#xD;
          -  History of active uncontrolled gastrointestinal disorders or diseases including:&#xD;
&#xD;
          -  Inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe),&#xD;
             Crohn's disease (mild-moderate-severe), or indeterminate colitis;&#xD;
&#xD;
          -  Irritable bowel syndrome (IBS) (moderate-severe);&#xD;
&#xD;
          -  Persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic&#xD;
             diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or&#xD;
             Helicobacter pylori infection (untreated)&#xD;
&#xD;
          -  Any confirmed or suspected condition/state of immunosuppression or immunodeficiency&#xD;
             (primary or acquired) including HIV infection.&#xD;
&#xD;
          -  Surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in&#xD;
             the past five years. Any major bowel resection at any time.&#xD;
&#xD;
          -  Confirmed or suspected autoimmune disease&#xD;
&#xD;
        Medications:&#xD;
&#xD;
          -  Weight loss medications&#xD;
&#xD;
          -  Regular high dose aspirin&#xD;
&#xD;
          -  Regular use of prescription opiate pain medication&#xD;
&#xD;
        If taken in the past 2 months:&#xD;
&#xD;
          -  Systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous,&#xD;
             intramuscular or oral)&#xD;
&#xD;
          -  Corticosteroids (intravenous, intramuscular, oral, nasal or inhaled)&#xD;
&#xD;
          -  Cytokines&#xD;
&#xD;
          -  Methotrexate or immunosuppressive cytotoxic agents&#xD;
&#xD;
        Diet &amp; Lifestyle:&#xD;
&#xD;
          -  Recent history of chronic excessive alcohol consumption defined as more than five&#xD;
             1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or&#xD;
             five 5-ounce servings of wine per day; or &gt; 14 drinks/week.&#xD;
&#xD;
          -  Regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other&#xD;
             nicotine-containing products&#xD;
&#xD;
        Maternal chronic medical conditions:&#xD;
&#xD;
          -  Pre-gestational diabetes (T1 or T2)&#xD;
&#xD;
          -  History of gestational diabetes&#xD;
&#xD;
          -  On medication that is an immune modulators or chronic steroid use&#xD;
&#xD;
          -  Hyperemesis gravidarum&#xD;
&#xD;
        Pregnancy history:&#xD;
&#xD;
          -  Preterm birth&#xD;
&#xD;
          -  Recurrent pregnancy loss&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D Garnder, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tayler Hennings, MPH</last_name>
    <phone>650-723-8114</phone>
    <email>taylerkl@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Robinson, PhD</last_name>
    <phone>650-736-8577</phone>
    <email>jlmorris@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Justin Sonnenburg, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scarlett Karakash, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://med.stanford.edu/nutrition/research/upcoming-studies/fefifo-moms.html</url>
    <description>Study description</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Christopher Gardner</investigator_full_name>
    <investigator_title>Rehnborg Farquhar Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Immune function</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

